间充质干细胞修复肝损伤的机制及膜微粒的生物治疗潜力*

doi:10.3969/j.issn.1672-5069.2015.01.028

摘要/Abstract

摘要： 间充质干细胞（mesenchymal stem cells, MSCs）移植是治疗肝硬化和肝衰竭的重要方式。MSCs修复肝损伤的机制主要有三种：干细胞分化为肝细胞样细胞,旁分泌作用和免疫调节功能及膜微粒（microvesicles,MVs)介导的信号传递。目前的研究表明,MVs介导的RNAs传递在组织修复中发挥着至关重要的作用,MVs移植可能成为修复肝损伤的一种新方式。本文重点介绍了移植入肝脏的MSCs可能的作用机制和MVs的生物治疗潜力。

关键词: 肝损伤, 间充质干细胞, 膜微粒, 治疗

Abstract: Transplantation of mesenchymal stem cells（MSCs） is an promising way in the treatment of cirrhosis and liver failure. The possible mechanisms of MSCs in repair of liver injury are as follows：differentiation to hepatocyte-like cells,paracrine and immunomodulatory effects,and signal transmission mediated by microvesicles （MVs）. Results from present studies suggest that RNA carried by MVs has emerged as an important mechanism by which the stem cells may repair injured cells and MVs transplantation may become a new choice for improving decompensated liver functions. This review will discuss the possible mechanisms of intrahepatic transplanted MSCs and the potential of MVs in the treatment of liver injuries.

Key words: Liver injury, Mesenchymal stem cells, Microvesicles, Treatment

阮承兰, 陈从新. 间充质干细胞修复肝损伤的机制及膜微粒的生物治疗潜力^*[J]. 实用肝脏病杂志, 2015, 18(1): 97-100.

Ruan Chenglan, Chen Congxin. Application of mesenchymal stem cells and microvesicles in the treatment of patients with liver injuries[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 97-100.

参考文献

[1] 陈海鸥,胡小宣,刘红娟,等. 脐血干细胞移植治疗肝硬化的疗效观察. 中华肝脏病杂志,2010,18（7）：537-538.
[2] Mou XZ,Lin J,Chen JY,et al. Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells. J Zhejiang Univ Sci B,2013,14（11）:961-972.
[3] Khan AA,Shaik MV,Parveen N,et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant,2010,19（4）:409-418.
[4] Tomasoni S,Longaretti L,Rota C,et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev,2013,22（5）:772-780.
[5] 孙艳,段芳龄,陈香宇,等. 体外诱导人脐血间充质干细胞向肝细胞系细胞分化的研究. 胃肠病学和肝病学杂志,2004,13（3）：239-243.
[6] Avital I,Inderbitzin D,Aoki T,et al. Isolation, characterization,and transplantation of bone marrow-derived hepatocyte stem cells. Biochem Biophys Res Commun,2001,288（1）:156-164.
[7] 陈建锋,高毅,蒋泽生,等. 人骨髓干细胞异体内诱导分化为肝细胞的实验. 中国临床康复,2006,10（17）：164-167.
[8] 戈霞晖,白冲. 间充质干细胞发挥治疗作用的机制研究. 广东医学,2010,31（20）：2725-2727.
[9] 江敏华. 间充质干细胞的免疫调控在治疗肝衰竭中的作用及机制探讨. 苏州：苏州大学出版社,2011：312.
[10] Di Nicola M,Carlo-Stella C,Magni M,et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood,2002,99（10）:3838-3843.
[11] Jiang XX,Zhang Y,Liu B,et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood,2005,105（10）:4120-4126.
[12] Yannaki E,Athanasiou E,Xagorari A,et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol,2005,33（1）:108-119.
[13] Liu Y,Dulchavsky DS,Gao X,et al. Wound repair by bone marrow stromal cells through growth factor production. J Surg Res,2006,136（2）:336-341.
[14] Banas A,Teratani T,Yamamoto Y,et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol,2009,24（1）:70-77.
[15] Jimenez J J,Jy W,Mauro L M. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res,2003,109（4）:175-180.
[16] Morel O,Toti F,Hugel B,et al. Cellular microparticles:a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol,2004,11（3）:156-164.
[17] Dean WL,Lee MJ,Cummins TD,et al. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost,2009,102（4）:711-718.
[18] Kim HS,Choi DY,Yun SJ,et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res,2012,11（2）:839-849.
[19] Sato T,Iso Y,Uyama T,et al. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. Lab Invest,2011,91（4）:553-564.
[20] Camussi G,Deregibus MC,Bruno S,et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int,2010,78（9）:838-848.
[21] Herrera MB,Fonsato V,Gatti S,et al. Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell Mol Med,2010,14（6B）:1605-1618.
[22] Deregibus MC, Cantaluppi V,Calogero R,et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood, 2007,110（7）:2440-2448.
[23] Bruno S,Grange C,Deregibus MC,et al. Human mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol,2009,20（5）:1053-1067.
[24] 师玲玲. 人类脐血间充质干细胞移植对急性肝坏死大鼠模型治疗作用的研究. 广州：暨南大学出版社,2010：419.
[25] Bi B,Schmitt R,Israilova M,et al. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol, 2007,18（9）:2486-2496.
[26] Parekkadan B,van Poll D,Suganuma K,et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One,2007,2（9）:e941.
[27] Lai RC,Arslan F,Lee MM,et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res, 2010,4（3）:214-222.
[28] Reis LA,Borges FT,Simoes MJ,et al. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One,2012,7（9）:e44092.
[29] Bruno S,Grange C,Collino F,et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One,2012,7（3）:e33115.
[30] Gatti S,Bruno S,Deregibus MC,et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant,2011,26（5）:1474-1483.
[31] Sokolova V,Ludwig AK,Hornung S,et al. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces,2011,87（1）:146-150.
[32] Gholamrezanezhad A,Mirpour S,Bagheri M,et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol,2011,38（7）:961-967.
[33] Chen TS,Lai RC,Lee MM,et al. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res,2010,38（1）:215-224.
[34] Kunter U,Rong S,Boor P,et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol,2007,18（6）:1754-1764.
[35] Thirabanjasak D,Tantiwongse K,Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol,2010,21（7）:1218-1222.

间充质干细胞修复肝损伤的机制及膜微粒的生物治疗潜力^*

Application of mesenchymal stem cells and microvesicles in the treatment of patients with liver injuries

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[5]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[6]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[11]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[12]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[13]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[14]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[15]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.